The Market Reports

Synopsis
The global market for Heparin Active Pharmaceutical Ingredients was estimated to be worth US$ 1225 million in 2024 and is forecast to a readjusted size of US$ 2301 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Heparin Active Pharmaceutical Ingredients cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. Most of the Heparin product is existed in a form of Heparin Sodium or Heparin Calcium. In this report, we mainly study the Heparin API.
Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. Most of the Heparin product is existed in a form of Heparin Sodium or Heparin Calcium. In this report, we mainly study the Heparin API.
The market driver mainly increasing prevalence of conditions such as renal impairment, coronary artery disease, and venous thromboembolism, High demand for anticoagulants, etc.
The expanding healthcare sector, coupled with a rising prevalence of cardiovascular diseases and thrombotic disorders, continues to drive demand for Heparin Active Pharmaceutical Ingredient (API). The growing global aging population and increasing awareness about these medical conditions have further intensified the need for effective anticoagulant therapies. Additionally, advancements in medical research and development, alongside the escalating number of surgical procedures, contribute to the sustained growth of the Heparin API market. While, one of the significant challenges in the Heparin API market is the vulnerability of its supply chain. Dependence on porcine mucosa as the primary source, coupled with supply disruptions due to disease outbreaks and geopolitical factors, poses a risk to consistent availability. Moreover, ensuring the quality and safety of Heparin APIs remains a concern, with regulatory scrutiny focused on preventing adulteration and contamination. Balancing these challenges while navigating competition from alternative anticoagulants and addressing complex production processes poses ongoing difficulties for industry stakeholders.
The classification of Heparin includes Heparin Sodium and Heparin Calcium. In 2024, Heparin Sodium accounted for a revenue share of 96.63% in the global Heparin market. In addition, this product segment is poised to reach US$ 2,228.35 million by 2031 from US$ 1,184.01 million in 2024.
Heparin is widely used for UFH and LMWH. In Heparin market, the LMWH holds an important share in terms of application, and it is expected to reach a value of US$ 1,977.66 million by 2031, at a CAGR of 7.94% during 2025 and 2031.
Europe is the largest consumption place, with a revenue market share nearly 36.86% in 2024. China is the worlds’ largest pig production, which supplied by sufficient raw materials.
North American market for Heparin API is estimated to increase from $ 431.49 million in 2025 to reach $ 671.33 million by 2031, at a CAGR of 7.65% during the forecast period of 2025 through 2031.
Asia-Pacific market for Heparin API is estimated to increase from $ 478.50 million in 2025 to reach $ 799.46 million by 2031, at a CAGR of 8.93% during the forecast period of 2025 through 2031.
Europe market for Heparin API is estimated to increase from $ 537.57 million in 2025 to reach $ 801.22 million by 2031, at a CAGR of 6.88% during the forecast period of 2025 through 2031.
The global key companies of Heparin Active Pharmaceutical Ingredients include Shenzhen Hepalink Pharmaceutical, Yantai Dongcheng Pharmaceutical, Nanjing King-friend Biochemical Pharmaceutical, Pfizer, Hebei Changshan Biochemical Pharmaceutical, Bioibérica, Qingdao Jiulong Biopharmaceutical, Changzhou Qianhong Biopharma, and Dongying Tiandong Pharmaceutical, etc. In 2024, the global five largest players hold a share approximately 55.0% in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Heparin Active Pharmaceutical Ingredients, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Heparin Active Pharmaceutical Ingredients by region & country, by Type, and by Application.
The Heparin Active Pharmaceutical Ingredients market size, estimations, and forecasts are provided in terms of sales volume (Billion Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Heparin Active Pharmaceutical Ingredients.
Market Segmentation
By Company
Yantai Dongcheng Pharmaceutical
Shenzhen Hepalink Pharmaceutical
Pfizer
Nanjing King-friend Biochemical Pharmaceutical
Bioibérica
Changzhou Qianhong Biopharma
Hebei Changshan Biochemical Pharmaceutical
Qingdao Jiulong Biopharmaceutical
Opocrin
Dongying Tiandong Pharmaceutical
Aspen Oss
Yino Pharma
Hubei Enoray Biopharmaceutical
Cisen Pharmaceutical
Segment by Type
Heparin Sodium
Heparin Calcium
Segment by Application
UFH
LMWH
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Heparin Active Pharmaceutical Ingredients manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Heparin Active Pharmaceutical Ingredients in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Heparin Active Pharmaceutical Ingredients in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index